...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: One More Promissory Note-Aug 9/24

Promissory Note: Dated 2024-08-09 for $ 549,280.00

With 550K warrants @ $1.03 expire, 2029-0-09

Out of Alberta (Accredited Investor)

 

Koo

 

Share
New Message
Please login to post a reply